Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: A press-coated tablet suitable for oral administration, comprising an immediate-release compartment comprising a compressed blend of an active agent. The immediate-release compartment has a dissolution profile in which 10-75% of the active agent is dissolved within one hour and not less than 90% of the active agent is dissolved within 6 hours. The tablet further comprises an extended-release compartment with a dissolution profile in which 5-40% of the active agent is dissolved within one hour, 20-75% within three hours, 40-95% of the active agent within 6 hours, and not less than 60% of the active agent is dissolved within 8 hours. Additionally, the press-coated extended-release compartment substantially envelops the immediate-release compartment, and comprises a compressed blend of the active agent, a hydrophilic polymer and hydrophobic material. The tablet exhibits a first order release of the active agent interrupted by a pulsed delivery of the active agent.

Abstract: The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.

Abstract: Dosage forms containing both immediate release and sustained release components for the treatment of ailments associated with depleted amounts of dopamine in brain tissue of a patient. The dosage forms contain a combination of carbidopa and levodopa.

Abstract: A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compare to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period.

Abstract: A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when compare to one another and when compared to that of the entire multiplex drug delivery unit, and substantially enveloped by a scored film coating that allows the separation of the multiplex drug delivery system into individual drug dosage packages can provide a convenient and cost effective drug delivery unit, particularly for patients with a regimen of prescribed dosages that varies during their treatment period.

Abstract: The present invention provides a drug delivery system for the oral administration of a hydrophobic active ingredient. The active ingredient's post-ingestion dissolution rate and its corresponding bioavailability can be optimized by intimately mixing a micronized hydrophobic drug with suitably sized inert particles to a dispersion that will facilitate desired bioavailability. In a particular embodiment, the hydrophobic active ingredient is fenofibrate. Suitably sized inert particles include microcrystalline cellulose and lactose. Dispersion may be monitored by microscopic visualization.

Abstract: The present invention provides a drug delivery system for the oral administration of a hydrophobic active ingredient. The active ingredient's post-ingestion dissolution rate and its corresponding bioavailability can be optimized by intimately mixing a micronized hydrophobic drug with suitably sized inert particles to a dispersion that will facilitate desired bioavailability. In a particular embodiment, the hydrophobic active ingredient is fenofibrate. Suitably sized inert particles include microcrystalline cellulose and lactose. Dispersion may be monitored by microscopic visualization.

Abstract: A press-coated tablet suitable for oral administration, comprising an immediate-release compartment comprising a compressed blend of an active agent. The immediate-release compartment has a dissolution profile in which 10-75% of the active agent is dissolved within one hour and not less than 90% of the active agent is dissolved within 6 hours. The tablet further comprises an extended-release compartment with a dissolution profile in which 5-40% of the active agent is dissolved within one hour, 20-75% within three hours, 40-95% of the active agent within 6 hours, and not less than 60% of the active agent is dissolved within 8 hours. Additionally, the press-coated extended-release compartment substantially envelops the immediate-release compartment, and comprises a compressed blend of the active agent, a hydrophilic polymer and hydrophobic material. The tablet exhibits a first order release of the active agent interrupted by a pulsed delivery of the active agent.

Abstract: A press coated, pulsatile drug delivery system suitable for oral administration having an immediate-release compartment, which contains a compressed blend of an active agent and one or more polymers, substantially enveloped by an extended-release compartment, which contains a compressed blend of the active agent and hydrophilic and hydrophobic polymers, can provide a substantially first order delivery of the active agent, interrupted by a timed, pulsed delivery of an increased amount of the active agent; and when the extended-release compartment is substantially enveloped by an optional instant-release compartment, can provide a dose sufficient to exceed the liver's metabolic capacity and to maintain therapeutic levels, preferably throughout a 24-hour period.

Abstract: A synchronizer that has reduced latency is used for synchronizing and conditioning a clock-enable signal to a free-running clock. Once the clock-enable signal is synchronized it is used to enable and disable gating of the free-running clock to a gated clock that suspends pulsing in response to the clock-enable signal. A first-stage flip-flop is `meta-stable hardened` to reduce the probability of it becoming meta-stable. Gating on the clock and the clear inputs reduces the chance that simultaneous inputs will violate the timing of the flip-flop and thus cause metastability. A clear pulse is generated to clear the flip-flop. The clear pulse skews the flip-flop to be more likely to become metastable for one edge of the asynchronous input than for the other edge. The settling time to the second stage flip-flop is then adjusted to account for this skew in metastability. Settling time in the second stage is increased for the edge that is more likely to become metastable.

Abstract: A substrate bias generator for an integrated circuit has a charge pump driven by an oscillator. The oscillator is enabled and disabled to save power and control the voltage-level itself for the substrate bias. An enabling circuit senses the substrate voltage and enables the oscillator when the substrate voltage rises above a bias set by a programmable reference voltage. The enabling circuit which senses the voltage on the substrate draws no active current from the substrate. The sensing circuit includes a transistor with only its bulk terminal connected to the substrate; the source, gate, and drain of this sensing transistor are not connected to the substrate. A differential comparator compares the output of the sensing transistor to the programmable reference voltage and enables the oscillator when the sensing transistor output is lower than the reference voltage.

Abstract: An all-CMOS output buffer drives a bus that can operate at 3 volts and 5 volts. When in a high-impedance state, the output buffer draws little or no current. If the bus is driven to 5 volts by an external device, the high impedance output buffer is in danger of latch-up and distortion of the bus logic level since it only has a 3-volt power supply and does not use a charge pump or an extra 5-volt supply. A biasing circuit couples an N-well that contains p-channel transistors and a driver transistor to the bus driven to 5 volts. Thus the N-well is also driven to 5 volts, the voltage on the bus. The gate of the p-channel driver transistor in the high-impedance output buffer is also coupled to the N-well by another p-channel transistor, raising the gate potential to 5 volts. Thus the gate and body of the p-channel driver transistor is at 5 volts, eliminating reversing current and latch-up problems. A transmission gate isolates the gate of the p-channel driver transistor from the rest of the device's circuitry.

Abstract: A multitude of non-tacky coated pellets containing a pharmaceutical preparation is housed within a breakable packet which, when broken, enables ready removal of the pellets for the oral administration of the preparation to a patient. The packet includes a bendable backing sheet and a fracturable covering member between which the pellets are held in a vacuum-sealed environment prior to use. The coating of the pellets also prevents dissolution of the preparation in the mouth to avoid the sensation of bitter medicinal taste.

Abstract: A pharmaceutical dosage unit suitable for masking the unpleasant taste of orally administered pharmaceutical agents and which facilitates swallowing comprises a plurality of subdosage units disposed within a container. Each subdosage unit is a pellet with an inner core coated with an active pharmaceutical agent, a first layer surrounding the core comprising a biologically inert excipient or filler, and a second layer surrounding the first layer comprising a mixture of a cationic copolymeric acrylate resin and a basic compound. The container of the dosage unit may be orally ingestible in itself, such as an openable gelatin capsule, or may be a frangible packet which must be opened in order to orally administer the subdosage pellets to a patient.